No abstract

Aim. In this article, we analyzed the age-related features of molecular- biological subtypes in 499 patients with invasive breast cancer. Materials and research methods. All cases were divided into 5 molecular- biological subtypes based on immunohistochemical studies of hormone receptors, Her2, Ki-67. Luminal (A and B) with the expression of estrogen and/or progesterone receptors (ER+/PR+), accounting for about 50-80% of all breast cancer cases and potentially sensitive, especially luminal A, to hormone therapy. Research results. The analysis showed that in our study the proportion of the Luminal A subtype was lower than the generally accepted values of 37.4% of all studied breast cancer cases. In the group of women under 40 years of age (with preserved menstrual-ovarian function), cases of Luminal A subtype were significantly less common (9.03%) compared to the groups of 41-50 years (p<0.006), 51-60 years (p<0.001), and over 60 (p<0.001). There was also a decrease in the proportion of Luminal A subtype among patients older than 60 years (p=0.0064). No significant differences were found between the groups 41-50 and over 60 years of age (p=0.1868).

The main treatment for cervical cancer are surgery, radiation and combined (surgery + radiotherapy), the role of chemotherapy in this localization is studied less fully. In recent years the new possibilities of chemotherapy, including neoadjuvant intraarterial chemotherapy, are explored. Theoretical prerequisites for this are the best drug delivery to the tumor by blood vessels, undamaged due to radiation therapy and surgery. This paper describes a clinical case of a patient with primary inoperable cervical cancer. As an alternative to preoperativ e radiotherapy the patient was proposed neoadjuv ant com bination chemotherapy with the use of regional administration of platinum drugs and systemic administration of drugs of taxan series as a stage of preparation for further surgical treatment. According to the prevalence of the tumor process patient underwent 2 courses of neoadjuv ant chemotherapy by a method of superselective intra-arterial administration of cisplatin and paclitaxel intravenously. According to a comprehensive examination after treatment data for the presence of tumor was absent. During the second stage the patient underwent surgical treatment in the volume of nerve-sparing radical hysterectomy with appendages. The next step, according to the histological form of the tumor, stage of disease, was the radiotherapy in the postoperative period on the pelv ic area and routes of lym ph drainage. The patient underwent external beam radiotherapy to the pelvic area of FD = 20 Gr, intracavitary gamma-therapy and external beam radiation on the area of parametrial and lymphopenia FD = 50 Gr.The patient passed the control examinations every 3 months. According to a comprehensive survey a year after the start of treatment — there is no data for the presence of recurrence and spread of tumor process.

В исследование были включены 256 пациентов с колоректальным раком (134 мужчины, 122 женщины) и 608 практически здоровых добровольцев (279 мужчин, 329 женщин). Генотипирование однонуклеотидных полиморфизмов I462V (rs1048943) CYP1A1, -154A>C (rs762551) CYP1A2 и L432V (rs1056836) CYP1B1 было проведено методом ПЦР в режиме реального времени. Полиморфизм rs1056836 CYP1B1 (замена L432V) ассоциировался с повышенным риском колоректального рака в популяции Центральной России: OR=1,48, 95%CI=1,07-2,04; р=0,02. A total of 256 patients with colorectal cancer (134 males, 122 females) and 608 age- and sex-matched healthy controls (279 males, 329 females) were recruited for the study. Genotyping of single nucleotide polymorphisms (SNPs) I462V (rs1048943) CYP1A1, -154A>C (rs762551) CYP1A2 and L432V (rs1056836) CYP1B1 were done using Taq-Man-based assays. Polymorphism rs1056836 (substitution L432V) CYP1B1 was associated with increased risk of colorectal cancer in the population from Central Russia: OR=1,48, 95%CI=1,07-2,04; p=0,02.

В исследование были включены 552 пациентки с миомой матки (ММ) и 337 женщин контрольной группы соответствующего возраста. Генотипирование однонуклеотидных полиморфизмов (rs713041 GPX4, rs4902346 GPX2, rs41303970 GCLM, rs17883901 GCLC, rs1050450 GPX1, rs1799811 и rs1695 GSTP1, rs2551715 GSR, rs1801310 GSS, rs4820599 GGT1, rs7674870 SLC7A11) было проведено методом ПЦР в режиме реального времени; генотипирование делеционных полиморфизмов (+/0 GSTM1 и +/0 GSTT1) было проведено методом мультиплексной ПЦР. С повышенным риском развития ММ ассоциировался rs7674870 SLC7A11 (OR=1,25, 95%CI=1,03-1,50; p=0,02). Полиморфизм rs2551715 GSR обладал протективным эффектом относительно развития заболевания (OR=0,83, 95%CI=0,70-0,99; p=0,04). A total of 552 females with uterine fibroids and 337 age-matched healthy controls were recruited for the study. Genotyping of single nucleotide polymorphisms (SNPs) of rs713041 GPX4, rs4902346 GPX2, rs41303970 GCLM, rs17883901 GCLC, rs1050450 GPX1, rs1799811 and rs1695 GSTP1, rs2551715 GSR, rs1801310 GSS, rs4820599 GGT1, rs7674870 SLC7A11 were done using Taq-Man-based assays. Genotyping of +/0 GSTM1 and +/0 GSTT1 polymorphisms were done using multiplex PCR. Polymorphism rs7674870 SLC7A11 was associated with increased risk of uterine fibroids (OR=1.25, 95%CI=1.03-1.50; p=0.02); rs2551715 GSR was associated with decreased risk of disease (OR=0.83, 95% CI=0.70-0.99; p=0.04)